Evidence map›Paper›PMID 31022877›Full record

ReviewInternational journal of molecular sciences2019

Natural Product Mediated Regulation of Death Receptors and Intracellular Machinery: Fresh from the Pipeline about TRAIL-Mediated Signaling and Natural TRAIL Sensitizers.

Durray Shahwar, Muhammad Javed Iqbal, Mehr-Un Nisa, Milica Todorovska, Rukset Attar, Uteuliyev Yerzhan Sabitaliyevich, Ammad Ahmad Farooqi, Aamir Ahmad, Baojun Xu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Molecular basis of acute coronary syndrome.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 7 countries.

Durray ShahwarLaboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore 54840, Pakistan. durrayshahwar.kh@gmail.com.
Muhammad Javed IqbalDepartment of Biochemistry and Biotechnology, University of Gujrat, Gujrat 34120, Pakistan. m.javediqbal@uog.edu.pk.ORCID 0000-0002-2035-4004
Mehr-Un NisaNational Institute of Food Science and Technology, UAF, Faisalabad 38000, Pakistan. mehru912@gmail.com.
Milica TodorovskaDepartment of Pharmacy, Medical Faculty, University of Niš, Dr Zorana Djindjica Boulevard 81, 18000 Niš, Serbia. mimatod@gmail.com.
Rukset AttarDepartment of Obstetrics and Gynecology, Yeditepe University, Ataşehir/İstanbul 34755, Turkey. ruksetattar@hotmail.com.ORCID 0000-0001-8770-9562
Uteuliyev Yerzhan SabitaliyevichKazakhstan Medical University "KSPH", Almaty 050060, Kazakhstan. e.uteuliyev@ksph.kz.
Ammad Ahmad FarooqiLaboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore 54840, Pakistan. ammadfarooqi@rlmclahore.com.
Aamir AhmadDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA. aahmad@health.southalabama.edu.ORCID 0000-0003-1784-5723
Baojun XuFood Science and Technology Program, Beijing Normal University-Hong Kong Baptist University United International College, Zhuhai 519087, Guangdong, China. baojunxu@uic.edu.hk.ORCID 0000-0003-0739-3735
Rashid Latif Medical College · PKBeijing Normal-Hong Kong Baptist University · CNKazakhstan Medical University · KZUniversity of Nis · RSUniversity of SialkotUSA Mitchell Cancer Institute · USYeditepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapidly developing resistance against different therapeutics is a major stumbling block in the standardization of therapy. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated signaling has emerged as one of the most highly and extensively studied signal transduction cascade that induces apoptosis in cancer cells. Rapidly emerging cutting-edge research has helped us to develop a better understanding of the signaling machinery involved in inducing apoptotic cell death. However, excitingly, cancer cells develop resistance against TRAIL-induced apoptosis through different modes. Loss of cell surface expression of TRAIL receptors and imbalance of stoichiometric ratios of pro- and anti-apoptotic proteins play instrumental roles in rewiring the machinery of cancer cells to develop resistance against TRAIL-based therapeutics. Natural products have shown excellent potential to restore apoptosis in TRAIL-resistant cancer cell lines and in mice xenografted with TRAIL-resistant cancer cells. Significantly refined information has previously been added and continues to enrich the existing pool of knowledge related to the natural-product-mediated upregulation of death receptors, rebalancing of pro- and anti-apoptotic proteins in different cancers. In this mini review, we will set spotlight on the most recently published high-impact research related to underlying mechanisms of TRAIL resistance and how these deregulations can be targeted by natural products to restore TRAIL-mediated apoptosis in different cancers.

Indexed as

AnimalsApoptosisBiological ProductsHumansNeoplasmsReceptors, Death DomainReceptors, TNF-Related Apoptosis-Inducing LigandSignal TransductionTNF-Related Apoptosis-Inducing LigandBiological ProductsReceptors, Death DomainReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing Ligandapoptosiscancerdeath receptorsnatural productsTRAIL

Identifiers

PMID31022877
PMCPMC6515249
OpenAlexW2942112791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.